Peter Hartog, Helmholz Zentrum München, Germany and AstraZeneca AB, Sweden
Emma Svensson, Johannes Kepler Universität Linz, Austria and AstraZeneca AB, Sweden
Paula Torren Peraire, Helmholz Zentrum München, Germany and Janssen Pharmaceutica NV, Belgium; now postdoc at Novartis
Dr. Varvara Voinarovska, Helmholz Zentrum München, Germany, AstraZeneca AB, Sweden and Enamine Limited Liability Company, Ukraine; PhD defended on 17th October, 2024 at Technical University of Munich; now postdoc at AstraZeneca
Dr. Julian Cremer, Universitat Pompeu Fabra, Spain and Pfizer Pharma GmbH, Germany; PhD defended on 28th November, 2024 at Universitat Pompeu Fabra; now postdoc at Pfizer Pharma GmbH
Son Hà, TU Dortmund, Germany/Johannes Gutenberg-Universität Mainz and Janssen Pharmaceutica NV, Belgium.
Alan Kai Hassen, Universiteit Leiden, Netherlands and Pfizer Pharma GmbH, Germany
Ana Sánchez Fernández, Johannes Kepler Universität Linz, Austria and Janssen Pharmaceutica NV, Belgium
Yasmine Nahal, AstraZeneca AB, Sweden and Aalto University, Finland.
Rosa Friesacher, Katholieke Universiteit Leuven, Belgium and AstraZeneca AB, Sweden.
Vincenzo Palmacci, Bayer Aktiengesellschaft, Germany and University of Vienna, Austria
Mikhail Andronov, Scuola Universitaria Professionale della Svizzera Italiana, Switzerland and Pfizer Pharma GmbH, Germany
Alessio Fallani, Université du Luxembourg and Janssen Pharmaceutica NV, Belgium
Muhammad Arslan Masood, Aalto University, Finland and Janssen Pharmaceutica NV, Belgium.
Mathias Hilfiker, Université du Luxembourg and AstraZeneca AB, Sweden.
Dr. Mariia Radaeva, Vancouver Prostate Center, The University of British Columbia, Canada; PhD defended 23rd August, 2024 at The University of British Columbia; now Board Member of Innovation OnBoard